Desymmetrizing C–H Activation Enables Concise Total Synthesis of (

Desymmetrizing C–H Activation Enables Concise Total Synthesis of (–)-Maximiscin

(–)-Maximiscin (1, Figure 1A) is a unique 4-hydroxy-2-pyridone alkaloid, a class of natural products historically represented by fascinating structural components and intriguing biological activities. Recently, 1 has been shown to induce DNA damage, activate DNA damage response pathways, and induce selective cytotoxicity against triple negative breast cancer (TNBC). The Baran group has reported the first total synthesis of 1 in a longest linear sequence of 10 steps. Their strategic bond disconnections are shown in Figure 1B.

The synthesis is summarized in Scheme 1, and showcases a C–H methoxylation step that acts to desymmetrize the pseudosymmetric α-carbon of compound 10 (note that 8 is achiral and directing group 9 is enantiopure) to afford 11. Notably, this is the most complicated example of this methodology, however there is a caveat to note, and it’s generally the “Achille’s Heel” of modern C–H activation methods, and that is the subsequent removal of the directing group (i.e., aqueous HBr, 100 C, 15 h). Not many substrates will survive conditions like this; however, many substrates used in medicinal chemistry (aromatic and heteroaromatic rings) are quite stable and thus these methods can be employed in the design of druglike molecules.

Other key transformations include an Ag/Fe co-catalyzed stereoinvertive decarboxylative Giese addition, followed by 1,5 hydrogen atom transfer (HAT) and radical oxidation (i.e., 12 to 14, Scheme 1), and an “Aza-Sakurai” cascade to construct the atropisomeric pyridone ring in the penultimate step (i.e., 5 + 6 to 18, Scheme 1). Given the creativity of the synthetic design, its biological relevance, and its first total synthesis, this manuscript can be considered suitable for publication in JACS.

Reference: McClymont, K. S.; Wang, F.-Y.; Minakar, A.; Baran, P.S. J. Am. Chem. Soc. 2020 (Just accepted April 25, 2020; doi:10.1021/jacs.0c03202

Comments

Photoswitchable azopyrazoles Flipping the Switches of Ion Channels

Abnormally activated Ca 2+ channels are related to many human diseases, including Stormorken Syndrome, which makes Ca 2+ release-activated Ca 2+ (CRAC) channel a very promising therapeutic target. Several small molecule therapeutics targeting CRAC channels have been developed, including the GSKs series and Synta 66 . Those compounds have relatively high specificity. Meanwhile, a controllable system that can be activated with a switch can probably serve as a convenient tool for further related research. Photoswitchable chemistry has been applied to a lot of bioactive targets such as ion channels, receptors enzymes and nucleic acids. Recently, the Li group developed CRAC channel inhibitors that can be turned ‘on’ and ‘off’ by UV-light exposure. Scheme 1 . C onverting CRAC channel inhibitors, GSKs , into photoswitchable derivatives, piCRACs . Starting from the well-established GSK-based CRAC inhibitor ( Scheme 1 ), the authors developed a series of nitr...

RIPK2 PROTAC Burns up the Bridges between PK and PD

GlaxoSmithKline (GSK) previously reported a series of RIPK2 PROTACs with various E3 ligase binders (Figure 1). These PROTACs can degrade RIPK2 potently and efficiently in a concentration-dependent manner (Figure1). However, their poor solubility and high microsomal clearance limited their in vivo applications. To develop a RIPK2 degrader suitable for in vivo applications, the GSK group identified another IAP based RIPK2 PROTAC4 that is significantly different from PROTAC2, possessing a different RIPK2 binder, IAP ligase binder and linker (Figure2). PTROTAC4 can degrade RIPK2 in a time-dependent manner and shows reduced lipophilicity and lower clearance in hepatocytes. However, the modest binding affinity between the warhead of PROTAC4 and RIPK2 requires a high dose to reach efficient RIPK2 degradation. To address this limitation, the researchers performed extensive medicinal chemistry optimization based on PROTAC 4 and identified PROTAC 6 (Figure2), which contains an...

Proteosome Inhibition Taps Into RNA Splicing

Multiple myeloma (MM) is a malignancy of white blood cells called plasma cells that reside mainly in the bone marrow and is the second most common blood cancer. With increased understanding of biology, the current use of immunomodulatory (IM) drugs and proteasome inhibitors (PI) have taken over the therapeutic landscape for MM. The combination of bortezomib (PI) with lenalidomiede (IM) and dexamethasone is commonly the initial treatment of choice. Early intervention seems to provide a good outcome, but unfortunately, many patients eventually relapse. A major goal in MM treatment is to increase the efficacy of proteasome inhibitors and prevent relapse. To investigate this, Huang et al. used unbiased mass spectrometry-based phosphoproteomics to identify potential vulnerabilities after treatment with the PI carfilzomib and discovered that splicing related proteins had significant changes in phosphorylation that is undetectable upon examination of RNA and protein abundance. Treatment w...

Quantitative Chemical Biology

Search This Blog